Oct 14, 2020
Mark Erlander, Chief Executive Officer at #CardiffOncology, Inc. talks #KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal #Cancer (mCRC)...
Oct 7, 2020
Kathryn Ardizzone of KEI discusses COVID-19 vaccine and treatment contracts obtained by KEI from the USG under the Freedom of Information Act. The government's investment in COVID-19 vaccines and treatments. The Bayh-Dole Act and its implications for COVID-19 technologies, and efforts to get around the Bayh-Dole Act by...